Guidelines for poster preparation
Please prepare your poster in A1 portrait format (59cm wide x 84cm long). Do not laminate your poster or use heavy printing material. Further information about poster sizes can be found on the following link:
Posters larger than A1 will only be displayed subject to the availability of space.
Maximum capacity 10 A1 potrait posters
Please ensure you have appropriate permissions for the publication of your abstract from the original copyright holders. Should you wish your abstract not to be published, please notify us in writing at the time of abstract submission.
Posters will be displayed for the full duration of the event.Titles of accepted poster abstracts will be displayed below.
(Presenters in Bold)
If your abstract has been accepted for presentation but it does not appear in the list below, please let us know as soon as possible by email on Exosomes@LPMHealthcare.com.
High-throughput, Purification-free, Multiplexed Profiling of Circulating miRNA for Discovery, Validation, and Diagnostics
Juan Hidalgo de-Quintana, M. Tackett, G. Doran, C. Rafferty, A. Windemuth, J. Tytell, D. Pregibon
Abcam plc, 330 Cambridge Science Park, Cambridge, CB4 0FL, UK
Abstract: We have developed the Multiplexed Circulating microRNA assay that allows the detection of up to 68 microRNA targets per sample. The assay combines particlebased multiplexing, using patented Firefly hydrogel particles, with single step RT-PCR signal. Thus, the Circulating microRNA assay leverages PCR sensitivity while eliminating the need for separate reverse transcription reactions and mitigating amplification biases introduced by target-specific qPCR. Furthermore, the ability to multiplex targets in each well eliminates the need to…
Characterization of microvesicles from human bronchial fibroblasts and their impact on the myofibroblastic differentiation during bronchial asthma*
Katarzyna Kmiotek1,2; Milena Paw1, Dawid Wnuk1, Ewa Zuba-Surma1, Marta Michalik1, Jarosław Czyż1
1 Jagiellonian University, Faculty of Biophysics, Biochemistry and Biotechnology, Department of Cell Biology, Krakow, Poland
2 Malopolska Centre of Biotechnology, Krakow, Poland
Abstract: Reports on the involvement of microvesicles (MVs) as the mediators of intercellular communication in the development of bronchial asthma prompted us to estimate their role in fibroblast-to-myofibroblast transition (FMT). It is a key process associated with the airway wall remodeling regulated by the multiple intercellular interactions and proinflammatory cytokines (include TGF-β1). Our recent findings show the involvement of connexin(Cx)43, a gap junctional protein, in the regulation of FMT in bronchial fibroblasts. Here, we focused for the first time on the identification and characterization of MVs derived from primary human bronchial fibroblasts (HBFs) isolated from asthmatic (AS) and healthy, non-asthmatic (NA) donors. Differences in transported cargo between AS MVs and NA MVs…
Host-parasite interactions: are vesicles from the Leishmania flagellum a source of virulence factors?
Laura Makin and Eva Gluenz
Sir William Dunn School of Pathology, South Parks Rd, Oxford, OX1 3RE, UK
Abstract:….My research investigates the possibility that during Leishmania differentiation flagellar membrane is shed in the form of vesicles which provide a virulence factor delivery mechanism. Differential centrifugation was used to isolate extracellular vesicles from differentiating parasite culture or a control promastigote parasite culture. Fluorescence imaging suggests that a sub-population of Leishmania extracellular vesicles is flagellar-derived. Mass spectrometric analysis was used to profile the protein content of isolated vesicles. Known virulence factors and known vesicle-associated proteins were enriched in the differentiating sample in addition to a large number of uncharacterised proteins…
RASSF1C oncogene promotes invasiveness in cancer cells through enhanced exosomes release
Maria Laura Tognoli, Nikola Vlahov and Eric O’ Neill
CRUK/MRC Oxford Institute for Radiation Oncology, Old Road Campus Research Building, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, UK
Abstract: RASSF1 (RAS association domain family 1) is one of the most frequently epigenetically inactivated tumour suppressor genes in sporadic human malignancies. High promoter methylation has been shown to associate with poor prognosis in breast, lung and colon cancers amongst others, and is being increasingly described as an independent prognostic indicator of overall survival in cancer patients. Correspondingly, RASSF1A protein has roles in a variety of key biological processes that restrain the development of cancer: apoptosis, cell cycle regulation, mitosis, and microtubule dynamics. However, in tumours with RASSF1 promoter methylation an alternative isoform…